New Options For Patients With Sarcoma

Adolescent and young adult (AYA) patients with sarcoma often fall into a medical “gray area” because they are too old for pediatric treatments but too young for adult protocols, causing them to miss out on many clinical trials. To change this, Dana-Farber Cancer Institute is using its unique setup—where pediatric and adult oncologists work side-by-side—to create clinical trials specifically for this age group. They are currently testing four groundbreaking therapies that target relapsed sarcomas in highly precise ways, offering new hope for treatments that have not changed significantly since the 1980s.

Instead of using traditional chemotherapy that attacks all fast-growing cells, these new treatments work like smart missiles. One approach uses “radioligand therapy” to deliver tiny, powerful radioactive packages directly to a specific protein on osteosarcoma cells. Another uses “bispecific antibodies” to act like matchmaking tape, physically pulling the body’s healthy immune cells right up to Ewing sarcoma cells to destroy them. The other two methods use engineered CAR T-cells to provide long-term cancer surveillance, and “protein degraders” that trick cancer cells into destroying the internal proteins they need to survive.

Read the full article